TGF-β / Smad Signaling
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
A8341 Go 6976Target: PKCSummary: PKCα/PKCβ1 inhibitor
-
A8342 GF 109203X1 CitationTarget: PKCSummary: Protein kinase C,MLCK,PKG and PKA inhibitor
-
A8604 GNF 5Target: Bcr-AblSummary: Bcr-Abl inhibitor
-
A8607 PPY ATarget: Abl kinasesSummary: Abl kinases inhibitor
-
B2286 K02288Target: ALKSummary: ALK inhibitor
-
B1404 DCC-2036 (Rebastinib)Target: FLT3|Bcr-Abl|Tie-2|KDRSummary: Bcr-Abl inhibitor
-
A3306 Chelerythrine ChlorideTarget: PKCSummary: PKC antagonist
-
A3478 HydroxyfasudilTarget: ROCK|Rho-kinaseSummary: Rho-kinase inhibitor and vasodilator
-
A3771 RKI-1447Target: ROCKSummary: Potent ROCK1/ROCK2 inhibitor
-
A3799 SB-505124 hydrochlorideTarget: ALKSummary: ALK5/ALK4/ALK7 inhibitor in TGF-β/activin signalling,selective